



Five Biopharma Companies Headline Industry Night at Cholangiocarcinoma Foundation Annual Conference

ArQule, ASLAN Pharmaceuticals, Delcath Systems, Inc, InnoPharmax and Leap Therapeutics to Present Clinical Trial Concepts to International Research Network

SALT LAKE CITY, UTAH, UNITED STATES, January 19, 2017 /EINPresswire.com/ -- The [Cholangiocarcinoma Foundation](#) (CCF) announced today that five biopharmaceutical companies have been selected to present their clinical trial concepts at the upcoming [Annual Conference](#) in Salt Lake City, Utah.



Truly, the best GI cancer meeting where the best science, most collaboration and meeting of the minds occurs year after year.”

Renuka Iyer, MD Roswell Park Cancer Institute

During the [Industry Night](#) event, representatives from ArQule, ASLAN Pharmaceuticals, Delcath Systems, Inc, InnoPharmax and Leap Therapeutics will present their clinical trial concepts to the International Cholangiocarcinoma Research Network (ICRN) which represents more than 30 investigators from 4 countries.

The purpose of Industry Night is to accelerate clinical trial development by fostering collaboration between the Foundation and industry partners. “Many global investigators are attending the conference, so it makes sense to invite colleagues from industry to participate and test their concepts. This is one of many ways the Foundation is accelerating development of potential new therapies for patients,” said CCF Board Member Sean Turbeville.

The CCF Conference will be held at the SLC Marriott City Creek on February 1-3 and be host to more than 250 professionals from 10 countries representing the medical and scientific communities, industry partners, policy-makers, payers, patients, caregivers and others invested in cholangiocarcinoma.

“We are grateful to Celgene, Ignyta, Incyte and Merck for providing \$10,000 each in educational support for the meeting” shared CCF Founder and President Stacie Lindsey. “Their support provides a forum to increase the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma.”

Additional funding for this conference was made possible (in part) by 1R13CA213778-01 from the National Cancer Institute and the Patient-Centered Outcomes Research Institute Eugene Washington PCORI Engagement Award.

About the Cholangiocarcinoma Foundation (CCF)

Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer).

About Cholangiocarcinoma

Cholangiocarcinoma is a “silent” form of cancer that originates from the cells lining the bile ducts. It is classified as a heterogeneous group of three anatomically distinct cancers grouped according to the location from which they arise: within the bile ducts (intrahepatic), outside the bile ducts (extrahepatic), and in between where the bile ducts exit the liver (perihilar).

The incidence and mortality of cholangiocarcinoma in North America and Europe has increased dramatically in the past few decades. In the US, there are approximately 6,000 new cases diagnosed each year. Because patients commonly present with symptoms that mimic those of other ailments, and there is no validated method of early detection, the majority of patients are diagnosed when the cancer is far too advanced to be removed by surgery. In these cases, chemotherapy and radiation therapy are the mainstay of treatment. The dismal 5-year survival rate for intrahepatic cholangiocarcinoma is estimated at 2-15%.

Donna Mayer
Cholangiocarcinoma Foundation
2153756362
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.